Latest Breaking News On - Escorihuela - Page 7 : comparemela.com

 E-Mail IMAGE: Joaquín Arribas, co-Program Director of Preclinical and Translational Research at VHIO, ICREA Professor, CIBERONC Investigator, Director of the Hospital del Mar Medical Research Institute (IMIM). view more  Credit: VHIO Redirection of lymphocytes, via T-cell bispecific antibodies (TCBs) and chimeric antigen receptors (CARs), is already approved to treat some hematologic malignancies. In solid tumors these immune-based strategies continue to fail. Research led by Joaquín Arribas, co-Program Director of Preclinical and Translational Research at VHIO, has now shown how HER2 breast cancer cells adopt a strategy to resist clearance by redirected lymphocytes. Findings evidence that the disruption of interferon-gamma signaling confers resistance to these immunotherapies and promotes disease progression.

Comunidad autonoma de catalunaComunidad autonoma de aragonRius ruizAlex martBreast cancer research foundationHealth institute instituto de salud carlosNature communicationsArriba growth factors groupHospital del mar medical research instituteSpanish associationFoundation comprehensive program of cancer immunotherapy immunologyTranslational researchProgram directorPostdoctoral fellowGraduate studentCorresponding author